Aprameya Engineering Limited
APRAMEYA (NSE) · ISIN INE0LQG01010 · Medical Equipment & Supplies · listed 2024
Not on any surveillance list
In Q2 FY25 (quarter to 30 September 2024, standalone), revenue was ₹9.27 cr and profit after tax −₹1.73 cr.
Next: Board meeting: financial results on 14 November 2026.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q2 FY25 standalone | ₹9.27 cr | −₹1.73 cr | −0.99 | 18 Dec 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹69.34 cr | ₹7.12 cr | ₹81.86 cr |
| 30 Sep 2025 standalone | ₹71.01 cr | ₹37.3 cr | ₹134.68 cr |
| 31 Mar 2025 standalone | ₹64.26 cr | ₹30.34 cr | ₹143.96 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 74.05% | 0.00% | 0.13% | 25.95% |
Latest filings
- Saurabh Kishorbhai Bhatt has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regul 23 July 2026 · NSE
- Saurabh Kishorbhai Bhatt has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regul 23 July 2026 · NSE
- Annual Report FY2025-26 (New) 8 July 2026 · NSE
- Aprameya Engineering Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 28 May 2026 · NSE
- Aprameya Engineering Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. 28 May 2026 · NSE
Other companies in Medical Equipment & Supplies
- Poly Medicure Limited
- Molbio Diagnostics Limited
- Tarsons Products Limited
- Vasa Denticity Limited
- Fabtech Technologies Limited
- Laxmi Dental Limited
- Nureca Limited
- QMS Medical Allied Services Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.